We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




HLA Primer Sets Achieve High- and Medium-Resolution Genotyping

By LabMedica International staff writers
Posted on 05 Apr 2011
New HLA Primer Sets achieve high- and medium-resolution genotyping of class I and class II loci of the Human Leukocyte Antigen (HLA) genes.

Introduced by 454 Life Sciences (Branford, CT, USA), a Roche Company, the new GS GType New HLA Primer Sets are designed for use with the company's benchtop GS Junior and GS FLX next-generation sequencing systems–enabling high-resolution typing and unambiguous allele assignment in a single run.

The kits are the first in a series of assays in the areas of immunogenetics, infectious disease, and cancer to be launched for use with 454 Sequencing Systems, allowing scientists to integrate easily the platforms into application-specific laboratory workflows.

The HLA genes encode for the immune system proteins that recognize foreign cells and other antigens. More...
Accurate characterization of an individual's HLA type is important for tissue transplantation matching, while variations in these genes have known association with a wide variety of autoimmune diseases, infectious diseases, and some cancers.

The long, clonal reads provided by 454 Sequencing Systems enable straightforward high-resolution of multiple samples at a time. In many cases HLA typing achieves unambiguous allele identification within a single sequencing run. Sequence output is compatible with third party HLA genotyping software tools – offering scientists a complete solution from DNA to genotype assignment.

Genotyping of HLA genes can be challenging because of the highly polymorphic nature of this region of the human genome. Traditional sequence-based typing using Sanger capillary electrophoresis technology is unable to resolve ambiguities and set phase without requiring multiple iterations, interspersed with significant manual analysis of the data, and often the use of multiple technologies.

The GS GType HLA Primer Sets are the result of an extensive multisite study, which was published March, 2011 in the journal Tissue Antigens.

"454Sequencing Systems offer a major advance for high-resolution, high-throughput HLA typing,” explained Henry Erlich, PhD, senior study author and Director of the Department of Human Genetics at Roche Molecular Systems. "The ability to quickly achieve such high accuracy and resolution will have a significant impact on research and, ultimately, on clinical application of HLA typing.”

Related Links:
454 Life Sciences


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.